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Samuele Baldasseroni, Edoardo Mannucci, Claudia Di Serio, Francesco Orso,
Nadia Bartoli, Enrico Mossello, Alice Foschini, Matteo Monami, Paolo Valoti,
Stefano Fumagalli, Claudia Colombi, Silvia Pellerito, Gianfranco Gensini,
Niccolo` Marchionni and Francesca TarantiniObjectives The aim of this study was to evaluate resistin
levels in patients with coronary artery disease (CAD) with or
without chronic heart failure, in order to define its
independent predictor.
Methods One hundred and seven outpatients with CAD
were enrolled in the study and divided into three groups:
CAD without left-ventricular systolic dysfunction (group 1);
CAD with left-ventricular dysfunction without heart failure
symptoms (group 2); CAD with overt heart failure (group 3).
Plasma resistin was determined by ELISA.
Results Resistin progressively increased from group 1
(10.7W5.0ng/ml) to groups 2 (11.8W5.8ng/ml) and 3
(17.0W6.8ng/ml), with the difference reaching statistical
significance in group 3 versus groups 1 and 2 (PU0.001).
A multivariable model of analysis demonstrated that the
best predictor of plasma resistin level was the estimated
glomerular filtration rate (P<0.001), indicating that reduction of
kidney function was the main cause of the adipokine increase
observed in patients with CAD and overt heart failure.opyright © Italian Federation of Cardiology. Unau
1558-2027  2012 Italian Federation of CardiologyConclusions Our data confirm the rise of resistin plasma
levels previously described in patients affected by chronic
heart failure; however, in our study, this relationship
seemed to be mediated mainly by the level of kidney
function, and only partially by the severity of ventricular
dysfunction.
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Adipose tissue is an active, endocrine organ that secretes
numerous bioactive peptides, called adipokines. Adipo-
kines affect several metabolic pathways1 and are involved
in glycometabolic homeostasis,2 inflammation,3 obesity,4
atherosclerosis and ischemic heart disease.5
Resistin, which is produced in humans by adipocytes
and monocytes,6 is an esameric adipokine that circulates
as high and low-molecular-weight isoforms, with
different biological activities.4 Resistin supports the
atherosclerotic process through the production of pro-
inflammatory cytokines,7 such as interleukin (IL)-8 and
monocyte chemotactic protein (MCP)-1, mediated by
the overexpression of nuclear factor (NF)-kB.8 Resistin
also promotes the expression of endothelin-1, vascular
cell adhesion molecule (VCAM)-1, intercellular adhesion
molecule (ICAM)-1 and several metalloproteinases,
leading to the onset and progression of endothelial
dysfunction.9 In addition, resistin stimulates migration
of macrophages and smooth muscle cells, from arterial
media to the intima, with the consequent formation of
foam cells.10 Murine cardiomyocytes, incubated withresistin, show a tumor necrosis factor (TNF)-a-mediated
glycometabolic dysregulation, resulting in cell damage, as
demonstrated by the elevation of creatine phosphokinase
(CPK) and troponin I.11
Clinical studies also reported elevated resistin concen-
trations in patients with chronic coronary artery disease
(CAD)12 and acute coronary syndromes, suggesting a
role for this adipokine as a marker of myocardial
ischemia in vivo.13 Increased resistin levels predicted
the incidence of myocardial infarction14 and were
associated with a higher risk of re-stenosis after
coronary angioplasty.15 Furthermore, resistin was inver-
sely correlated with left-ventricular ejection fraction
(LVEF), and directly correlated with measures of myo-
cardial damage, during myocardial infarction;13 in this
setting, elevated plasma levels of the adipokine predicted
mortality.16
Lastly, recent data from the Framingham Offspring
Study demonstrated that levels of resistin above
15 ng/ml were associated with an increased risk of
developing heart failure.17thorized reproduction of this article is prohibited.
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suggest that elevated resistin could contribute to myo-
cardial damage in patients with ischemic heart disease,
thus contributing to the pathogenesis of heart failure, the
possibility that reduced cardiac function is also a cause,
and not only a consequence, of the increased circulating
resistin cannot be dismissed.
The aim of this study was to evaluate resistin in patients
with CAD, with normal systolic function, with asympto-
matic left-ventricular dysfunction or with overt chronic
heart failure, and to identify its independent predictor, in
order to shed more light on the complex relationship that
exists between ischemic heart disease, cardiac function
and circulating levels of this adipokine.
Methods
Study participants
A consecutive series of Caucasian outpatients referred
for CAD to the Geriatric Cardiology and Medicine Unit
of Careggi Academic Hospital (Florence, Italy), between
1 January 2006 and 31 December 2008, were enrolled,
provided that they met the following inclusion criteria:
written informed consent, CAD documented by at least
one 75% stenosis of a major epicardial branch at coronary
angiography, no hospitalization for worsening heart
failure during the past 2 months. The study was approved
by an institutional review committee.
Clinical and instrumental data
A thorough clinical history, including all medications
used by the patient and symptoms needed to define
New York Heart Association (NYHA) class, was col-
lected. Patients underwent a physical examination with
measurement of height and weight to calculate body
mass index (BMI), 12-lead electrocardiogram (ECG),
and 6-min walking test.18 A standard echocardiographic
study was carried out following the American Society
of Echocardiography recommendations,19 using a
4-chamber apical view to calculate LVEF, according to
the Simpson’s formula.19 Heart failure was considered to
be overt in the presence of positive European Society of
Cardiology (ESC) criteria,20 coupled with a Boston score
of at least 5.21 Combining LVEF with ESC and Boston
criteria, patients were classified as group 1 (LVEF55%,
no overt heart failure; n¼ 46), 2 (LVEF <40%, no overt
heart failure; n¼ 24), and 3 (LVEF <40%, overt heart
failure; n¼ 37). Patients with LVEF in the 40–54% range
were excluded from the study in order to select patients
with markedly different left-ventricular systolic function.
The level of noncardiac comorbidity was measured with
the Greenfield’s Index of Disease Severity (IDS score),22
whereas the presence of depressive symptoms was
evaluated with the 30-item form of the Geriatric Depres-
sion Scale (GDS).23 Diabetes was diagnosed according to
American Diabetes Association (ADA) criteria.24pyright © Italian Federation of Cardiology. UnautBiochemical data
Venous blood samples were drawn in the fasting state to
determine glycemia, hemoglobin, glycated hemoglobin
(HbA1c, determined with the high liquid pressure
chromatographymethod;MenariniDiagnostics, Florence,
Italy; upper normal limit 5.9%), erythrosedimentation rate
(ESR), blood urea nitrogen (BUN), creatinine, uric acid,
fibrinogen and lymphocyte count. Glomerular filtration
rate (GFR)was estimated according to theModification of
Diet in RenalDisease (MDRD) Studymethod (eGFR).25
Circulating plasma resistin was determined, in duplicate,
by ELISA (Linco Research, Missouri, USA); N-terminal
pro-B-type natriuretic peptide (NT-proBNP) was mea-
sured with a chemiluminescent immunoassay kit (Roche
Diagnostic Laboratory, Indianapolis, Indiana, USA) on an
Elecsys 2010 analyzer.
Statistical analysis
Data were analyzed using SPSS software (version 17;
SPSS Inc., Chicago, Illinois, USA) and are presented
as meanSD or median (quartiles), depending on
their normal or non-normal distribution, for continuous
variables, and as number (%) for categorical ones.
Categorical and continuous variables were compared
across the three groups (1, 2 and 3) using chi-square test
and analysis of variance (ANOVA), respectively. The
association of resistin levels with demographic, clinical,
pharmacological, echocardiographic and biohumoral
variables, after adjusting for age, sex and BMI, was
verified using a stepwise multiple linear regression
model. For each aspect (demographic, clinical, pharma-
cological, echocardiographic and biohumoral), variables
that showed the best association with resistin were
entered into a multivariable, stepwise regression model,
with re-coding categorical variables as 0/1 dummy
variables, to sort those with the highest significant inde-
pendent correlation. In case of more than one statistically
significant association within a predefined aspect, only
one variable was included in the regression model, to
avoid co-linearity; this sorted variable had the highest b
coefficient/SE ratio (Wald test). Finally, differences in
plasma resistin levels across the three groups were
adjusted in the ANOVA model using as covariate the
best independent predictor of plasma resistin levels.
A P value less than 0.05 was considered statistically
significant.
Results
Characteristics of the study population
One hundred and seven patients, aged 67.7 10.3 years
(range 38–90), were enrolled in the study; 13 were women
(11.8%); mean value of BMI was 26.7 4.0kg/m2. Cardio-
vascular comorbidity was distributed as follows: 74% of
patients had previous myocardial infarction; 46% under-
wentmyocardial revascularization (cardiac bypass surgery
or coronary angioplasty); 19% had persistent/permanenthorized reproduction of this article is prohibited.
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Plasma levels of resistin in the three heart failure groups.atrial fibrillation. Hypertension was present in 66%, dia-
betes in 42%andhypercholesterolemia in 68%ofpatients.
The mean distance walked in 6min was 454.9 164.0m;
mean LVEF was 44.1 15.3%, 20.9% of patients were
classified as NYHA III–IV. Among biohumoral variables,
mean fasting glucose was 120.4 47.4mg/dl, BUN
54.8 30.0mg/dl, eGFR 70.6 27.4ml/min, total choles-
terol 176.0 41.4mg/dl, uric acid 5.9 1.8mg/dl and
hemoglobin level 12.04 4.74mg/dl. Mean NT-proBNP
concentration was 2154.3 4580.9 ng/l.
Mean plasma resistin concentration was 13.4 6.5 ng/ml,
with a significantly higher level in group 3 patients in
comparison with groups 1 and 2 (Fig. 1). According to
evidence-based guidelines, the majority of patients were
treated with angiotensin-converting enzyme (ACE)-
inhibitors/angiotensin receptor blockers (ARBs) (87%),
beta-blockers (80%) and antiplatelet agents (83%).
Differences across the three groups
As reported in Table 1, patients in group 3 were
significantly older, had lower BMI, higher comorbidity,
less frequently underwent percutaneous coronary angio-
plasty, and presented more frequently depressive symp-
toms and a history of atrial fibrillation. Patients in groups
2 and 3 had a higher rate of previous myocardial infarc-
tion. As expected, indicators of symptomatic heart failure,
such as high NYHA class, signs and symptoms of
pulmonary and systemic fluid retention, were more
commonly detected in group 3 patients. Patients in
groups 2 and 3 had echocardiographic parameters indi-
cating enlargement of cardiac chambers. Moving from
group 1 to 3 we registered a progressive reduction of E
wave deceleration time (Tdec) and an increase in E/Aopyright © Italian Federation of Cardiology. Unauratio, suggestive of worsening left-ventricular diastolic
function. Patients in group 3 had a significantly higher
tricuspid pressure gradient, an indirect indicator of
elevated pulmonary artery pressure. Among the bio-
humoral variables, a significant, progressive reduction
in eGFR was registered from group 1 to group 3, with
a parallel progressive increase of BUN. All three bio-
humoral inflammatory markers (uric acid, fibrinogen and
ESR) showed a gradual increase across the three groups
(Table 1). Lastly, according to clinical severity, NT-
proBNP progressively increased from group 1 to group 3.
Group 3 patients were treated more frequently with
digoxin, diuretics, nitrates and warfarin, and less
frequently with calcium antagonists, statins and anti-
platelet agents. No significant differences were detected
in the use of ACE/ARB or beta-blockers among the
three groups.
As reported in Fig. 1, plasma resistin levels showed
a progressive elevation from group 1 to 3, with the
difference reaching statistical significance in group 3,
compared with groups 1 and 2 (P¼ 0.001 and
P¼ 0.001, respectively).
Predictors of plasma resistin level
As reported in Table 2, in the anamnestic-demographic
aspect, a statistically significant association was found
between comorbidity and higher resistin; in the clinical
functional aspect, increasing resistin level was associated
with decreasing of distance walked in 6 min and higher
NYHA class; in the echocardiographic aspect the E/A
ratio was the only independent predictor, whereas in the
biohumoral one eGFR and ESRwere both able to predict
resistin levels. Finally, in the pharmacological aspect, the
only predictor was the use of digoxin. When the best
predictors of each aspect were pooled in the full model of
analysis (Table 3), the strongest indicator of plasma
resistin level was eGFR, suggesting that the reduction
of kidney function was the main cause of adipokine
increase (P< 0.001). The highly significant, inverse
relation between eGFR and resistin levels is reported
in Fig. 2. In the adjusted ANOVA model, including
eGFR as covariate, the difference in plasma resistin
levels across the three groups still remained statistically
significant (P¼ 0.03) (Table 4).
Discussion
In the pathogenesis of atherosclerosis the role of
inflammation has been clearly established;26 resistin
may represent the link between inflammatory mediators
and endothelial promoters of atherogenesis.3 Indeed,
expression of resistin is up-regulated during mono-
cyte–macrophage differention,27 and pro-inflammatory
mediators, such as TNF-a, stimulate the expression of
resistin in peripheral blood mononuclear cells.28 In turn,
resistin promotes endothelial cell activation through
the production of adhesion molecules and monocytethorized reproduction of this article is prohibited.
Co
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Table 1 Characteristics of the study population
Group 1 (n¼46) Group 2 (n¼24) Group 3 (n¼37) P value
Anamnestic and demographic aspect
Age, years 67.18.1 61.511.3 72.49.9 0.001
BMI, kg/m2 27.93.2 26.65.4 25.33.2 0.012
Female sex 13.0 8.3 3.5 0.788
Previous myocardial infarction 60.8 87.5 86.4 0.008
Previous angina 52.2 41.7 35.1 0.287
Previous CABG 28.3 29.2 27.0 0.993
Previous PCI 76.1 87.5 59.5 0.053
Smokers 54.3 54.2 45.9 0.918
Hypertension 71.7 54.2 73.0 0.242
Hypercholesterolemia 76.1 75.0 59.5 0.217
Atrial fibrillation 17.4 0.0 35.1 0.003
Diabetes 52.2 29.2 37.8 0.112
COPD 4.3 8.3 21.6 0.041
Comorbidity level-IDS score 2.51.8 2.32.4 4.21.8 <0.001
Depressive symptoms-GDS score 6.04.8 6.64.8 10.15.6 0.002
Clinical and functional aspect
Distance at 6-WT, m 499.0134.8 517.7156.1 340.0154.3 0.001
NYHA class 1.10.2 1.10.3 2.70.7 <0.001
Jugular vein distension 4.3 0.0 29.0 0.001
Third heart sound 0.0 0.0 18.9 0.001
Pulmonary rates 8.7 0.0 43.2 0.001
Leg edema 6.5 8.3 35.1 0.001
Echocardiographic aspect
Left atrial diameter, mm 39.75.2 42.45.7 46.97.4 0.001
End systolic diameter, mm 52.74.3 63.914.3 69.57.0 0.001
End diastolic diameter, mm 35.45.8 50.97.3 58.27.4 0.001
IVRT, ms 87.923.8 102.125.1 91.917.2 0.073
E/A ratio 1.00.3 1.10.8 2.12.0 0.001
Ejection fraction 59.86.4 34.44.9 29.14.5 <0.001
Tdec, ms 215.357.1 202.452.5 183.881.6 0.135
Myocardial mass g/m2 110.522.1 142.237.8 148.030.7 0.001
Trans-tricuspidal gradient, mmHg 8.513.6 7.115.2 20.921.9 0.003
Biohumoral aspect
Fasting blood glucose, mg/dl 121.247.2 117.732.5 121.356.7 0.950
eGFR, ml/min 81.929.8 73.819.9 55.722.1 0.001
Hemoglobin, g/dl 13.91.3 13.71.7 13.11.6 0.075
HbA1c, % 6.81.5 6.31.0 6.71.3 0.467
ESR, mm/h 27.617.8 33.225.0 51.430.1 0.001
Fibrinogen, mg/dl 410.994.1 432.3118.3 478.898.8 0.015
Uric acid, mg/dl 5.31.3 6.11.7 6.52.1 0.009
Lymphocyte, % 27.28.3 28.19.2 24.012.2 0.256
Total cholesterol, mg/dl 174.135.0 187.845.7 170.645.0 0.269
HDL, mg/dl 43.610.8 44.89.9 40.911.6 0.360
BUN, mg/dl 45.921.7 51.022.6 68.237.8 0.003
NT-proBNP, ng/l 582.31022.1 2108.63798.0 4367.26803.5 0.002
Pharmacological aspect
ACE-inhibitors/ARB 87.0 96.0 86.5 0.434
Beta-blockers 73.9 92.0 83.8 0.157
Diuretics 28.3 56.0 89.2 0.001
Antiplatelet agents 89.1 100.0 67.6 <0.001
Digoxin 8.7 16.0 45.9 <0.001
Warfarin 13.0 4.2 32.4 0.009
Antialdosterone agents 6.5 48.0 45.9 0.001
Calcium antagonists 43.5 8.0 10.8 0.001
Nitrates 26.1 20.0 48.6 0.029
Statins 80.4 80.0 57.8 0.035
Data are expressed as meansSD for continuous and as % for categorical variables. 6-WT, 6-min walking test; ACE, angiotensin-converting enzyme; ARB, angiotensin
receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; eGFR,
estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; GDS, geriatric depression scale; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; IDS,
index of disease severity; IVRT, isovolumic relaxation time; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous
coronary intervention; Tdec, transmitral E-wave deceleration time.chemoattractant protein (MCP)-1, promoting athero-
genesis.9 Resistin was detected in macrophages within
atherosclerotic lesions,7 and, recently, Xu et al.29 demon-
strated an involvement of the adipokine in macrophage
CD36 expression and lipid accumulation.30
Taken together, these data suggest a possible patho-
physiological role of resistin in cardiovascular diseasepyright © Italian Federation of Cardiology. Unautprogression. Indeed, resistin appeared to mediate the
myocardial damage induced by ischemia/reperfusion11
and to alter cardiomyocyte contractility and relaxation
velocities through the impairment of cytoplasmic calcium
clearing.31 In addition, the adipokine correlated with the
risk of re-stenosis after coronary stenting in diabetic
patients,15 and predicted mortality after acute myocardial
infarction.16horized reproduction of this article is prohibited.
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Table 2 Relationships between resistin level and variables grouped into anamnestic-demographic, clinical and functional,
echocardiographic, biohumoral and pharmacological aspects
Variable
Model 1
P value
Model 2§
P valueBeta (SE) Beta (SE)
Anamnestic and demographic aspect R¼0.65, P<0.001
Previous myocardial infarction (yes vs. no) 6.15 (6.70) 0.361
Previous PCI (yes vs. no) 0.04 (1.45) 0.997
Atrial fibrillation (yes vs. no) 1.08 (1.58) 0.497
COPD (yes vs. no) 2.32 (2.00) 0.250
Comorbidity level-IDS score 1.05 (0.30) 0.001 1.03 (0.31) 0.001
Depressive symptoms-GDS score 0.37 (0.12) 0.004 – –
Clinical and functional aspect R¼0.54, P<0.001
Distance at 6-WT, m 0.01 (0.01) <0.001 0.01 (0.00) 0.029
NYHA class 2.92 (0.67) <0.001 2.55 (0.74) 0.001
Jugular vein distension (yes vs. no) 2.06 (2.03) 0.202
Third heart sound (yes vs. no) 4.97 (2.41) 0.043 – –
Pulmonary rates (yes vs. no) 2.91 (1.71) 0.092
Leg edema (yes vs. no) 0.46 (1.75) 0.791
Echocardiographic aspect R¼0.52, P<0.001
Left atrial diameter, mm 0.22 (0.09) 0.020 – –
End systolic diameter, mm 0.12 (0.05) 0.015 – –
End diastolic diameter, mm 0.13 (0.05) 0.007 – –
E/A ratio 1.31 (0.52) 0.015 2.00 (0.55) 0.001
Ejection fraction 0.14 (0.04) 0.001 – –
Myocardial mass g/m2 0.02 (0.02) 0.153
Trans-tricuspidal gradient, mmHg 0.09 (0.04) 0.010 – –
Biohumoral aspect R¼0.70, P<0.001
Fasting blood glucose, mg/dl 0.03 (0.01) 0.046 – –
HbA1c, % 0.83 (0.49) 0.098
eGFR 0.14 (0.02) <0.001 0.14 (0.02) <0.001
Hemoglobin 1.08 (0.42) 0.011 – –
ESR 0.09 (0.03) 0.001 0.05 (0.02) 0.049
Fibrinogen 0.02 (0.01) 0.004 – –
Uric acid 0.65 (0.36) 0.074
Lymphocyte count 0.13 (0.06) 0.041 – –
BUN 0.09 (0.02) <0.001 – –
NT-proBNP 0.01 (0.01) 0.031 – –
Pharmacological aspect R¼0.42, P<0.001
Diuretics (yes vs. no) 2.66 (1.22) 0.032 – –
Antiplatelet agents (yes vs. no) 2.35 (1.69) 0.167
Digoxin (yes vs. no) 4.08 (1.44) 0.006 4.46 (1.41) 0.002
Antialdosterone agents (yes vs. no) 1.04 (1.37) 0.451
Calcium antagonists (yes vs. no) 0.21 (1.47) 0.888
Nitrates (yes vs. no) 0.70 (1.33) 0.600
Warfarin (yes vs. no) 3.21 (1.55) 0.041 – –
Statins (yes vs. no) 2.17 (1.41) 0.126
Model 1: adjusted for age, sex, BMI; model 2: stepwise backward regression model. Abbreviations: 6-WT, 6-min walking test; BMI, body mass index; BUN, blood urea
nitrogen; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; ESR, erythrocyte
sedimentation rate; GDS, geriatric depression scale; HbA1c, glycated hemoglobin; IDS, index of disease severity; IVRT, isovolumic relaxation time; NT-proBNP,
N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; Tdec, transmitral E-wave deceleration time.In our clinical setting, patients with CAD, without left-
ventricular systolic dysfunction, showed levels of resistin
(10.7 4.9 ng/ml) significantly higher than what was pre-
viously reported in healthy or in diabetic and nondiabetic,
obese patients,32 even higher than other series of patientsopyright © Italian Federation of Cardiology. Unau
Table 3 Independent predictors of plasma resistin level
R¼0.74 P<0.001
Multivariable model Beta (SE) P value
Age 0.05 (0.06) 0.409
Sex 1.02 (1.63) 0.535
BMI 0.03 (0.15) 0.829
Comorbidity-IDS score 0.27 (0.30) 0.361
NYHA class 0.47 (0.84) 0.581
E/A ratio 0.19 (1.35) 0.911
Digoxin 2.35 (1.52) 0.127
eGFR 0.14 (0.02) <0.001
BMI, body mass index; eGFR, estimated glomerular filtration rate; IDS, index of
disease severity; NYHA, New York Heart Association.with CAD.33 This finding could be explained by the
fact that our study population was older, and included
patients with chronic kidney disease that were excluded
by other studies.33 Moreover, in our patients, resistin
level correlated strongly with IDS score, a measure of
comorbidity, and with inflammatory markers (ESR and
fibrinogen). A correlation with inflammation has been
reported previously in patients with cardiovascular
disease33 and, more recently, in septic and nonseptic
critically ill patients.34
We detected a progressive increase in mean plasma
resistin levels from group 1 to group 3, although the
difference became statistically significant only in group
3. In our patients with overt heart failure, higher levels of
resistin correlated with indicators of functional capacity,
such as NYHA class and distance walked in 6 min. In a
cohort of hospitalized heart failure patients Takeishithorized reproduction of this article is prohibited.
Copyright © Italian Federation of Cardiology. Unaut
CE: Namrta; JCM/201417; Total nos of Pages: 8;
JCM 201417
6 Journal of Cardiovascular Medicine 2012, Vol 00 No 00
Fig. 2
40.00
30.00
20.00
10.00
0.00
40.00
30.00
20.00
10.00
0.00
40.00
30.00
20.00
10.00
0.00
30.00
25.00
20.00
15.00
10.00
5.00
0.00
R
es
is
ti
n
 n
g
/m
l
R
es
is
ti
n
 n
g
/m
l
R
es
is
ti
n
 n
g
/m
l
20.00 40.00 60.00 80.00
eGFR ml/min
eGFR ml/min
eGFR ml/min
Group 2
Group 1
p < 0.001
p < 0.001Total population
P < 0.001
100.00
0.00 20.00 40.00 60.00 80.00 100.00
120.00 140.00
0.00 20.00 40.00 60.00 80.00100.00120.00140.00
R
es
is
ti
n
 n
g
/m
l
eGFR ml/min
Group 3
p < 0.024
20.00 40.00 60.00 80.00 100.00
Correlation between resistin and kidney function estimated by glomerular filtration rate (eGFR), in the total study population and in the three groups.
Table 4 Unadjusted and adjusted ANOVAmodels of the difference
in plasma resistin levels among the three groups
Model 1 Model 2
Variable F P value F P value
Group classification 12.84 <0.0001 3.65 0.03
eGFR 40.10 <0.0001
Model 1: ANOVA unadjusted. Model 2: ANOVA adjusted for eGFR.et al.35 found a progressive increase in resistin
levels according to NYHA class, from a mean value
of 10 ng/ml in NYHA I, to a mean value of more than
20 ng/ml in NYHA IV. They also demonstrated that
patients with plasma resistin levels over 14 ng/ml had
a significantly higher risk of death.35 Interestingly, in our
series themean value of resistin (17.0 6.8 ng/ml) in group
3 patients, which were classified as NYHA III–IV, washorized reproduction of this article is prohibited.
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et al. series.
Estimated GFR, a sensitive indicator of kidney function,
was the main independent predictor of plasma resistin
level. This is an interesting finding because it links
the adipokine increase with the progressive reduction
in renal perfusion that often accompanies chronic heart
failure. The central role of eGFR in the rise of plasma
resistin levels was clearly described by Ellington et al.36 in
patients with hypertension, in whom higher resistin
is associated with lower eGFR. The association was
independent from the presence of CAD risk factors,
insulin resistance and inflammation.36 Similar results
were also reported by Axelsson et al.37 in a post-hoc,
cross-sectional study of 239 chronic kidney disease
(CKD) patients. In this setting, serum levels of resistin
were markedly elevated in CKD patients with mild to
moderate (eGFR 23.2 1.0 ng/ml) and severe (eGFR
39.9 1.3 ng/ml) renal impairment, compared to controls
(eGFR 8.5 0.7 ng/ml; P< 0.001).
The strong association of resistin with eGFR may
be explained by the ability of the adipokine, which is
a low-molecular-weight plasma protein, to freely filter at
the glomerulus; thus, a decrease in glomerular function
will result in an elevation of plasma resistin concen-
tration. However, using a mouse model of uremia, it
has been demonstrated that the production of reactive
oxygen species (ROS) that accompanies renal insuffi-
ciency, stimulated adipocytes to overexpress and release
resistin.38 Therefore, the link between kidney dysfunc-
tion and elevated plasma resistin concentrations may rely
onmore complex pathways than just glomerular filtration.
Further longitudinal studies will be necessary to confirm
the central role of kidney function in mediating resistin
increase in patients with heart failure. Moreover, in our
series, the interaction between severity of left-ventricular
dysfunction and resistin remained significant even after
adjusting for eGFR, indicating that the rise of adipokine
concentration is not fully explained by the level of
kidney function; the severity of heart failure per se or
other cytokines/adipokines not tested in this study (i.e.
TNF-a) may contribute to the increase of resistin.
A cross-sectional study such as this cannot establish
causal relationships; therefore, this investigation cannot
provide definitive conclusions on the pathophysiological
link between elevated resistin and myocardial dys-
function. However, there is evidence that resistin can
acutely impair cardiac muscle glucose utilization and
cardiomyocyte function.31,39
In addition, a further detrimental effect of resistin in
heart failure patients can be postulated based on the
results of Cohen et al.40 demonstrating that in uremic
and diabetic patients resistin was able to interfere with
the chemotactic movement and the oxidative burst of
polymorphonuclaear leukocytes, impairing the immuneopyright © Italian Federation of Cardiology. Unauresponse. Therefore, resistin could contribute to the
dysregulation of the immune system which is often
detected in patients with advanced, chronic heart
failure,41 increasing the susceptibility to lethal infections,
potentially affecting the prognosis of patients.42
Because in the present survey eGFR was the main
predictor of resistin concentrations, it can be speculated
that a vicious cycle could exist in patients with heart
failure, with elevated resistin contributing to the
deterioration of myocardial function, leading to an
impairment of renal blood flow, which, in turn, induces
an increase in resistin levels.
Some limitations of the present study need to be
mentioned: first, women represent only 12% of the entire
study population; second, the design of the study is
cross-sectional, precluding the analysis of a cause–effect
correlation between impaired kidney function and
resistin; third, no data have been collected on different
circulating resistin isoforms to evaluate their biological
activity and their relationship with eGFR; and, fourth,
the relation of resistin with other cytokines, such as TNF-
a and IL-6, was not tested.
In conclusion, our results confirm the elevated resistin
levels in CAD patients with overt heart failure compared
to those with normal systolic function or with systolic
dysfunction without any sign of heart failure. This
relationship seems to be mainly, but not completely,
mediated by kidney function and, specifically, by the
level of GFR. If longitudinal studies confirm this finding,
resistin should be considered an important player in the
metabolic mechanisms that link atherosclerosis, the onset
and progression of renal insufficiency and the severity of
heart failure in coronary artery disease patients.
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